When patients with melanoma become resistant to mitogen-activated protein kinase (MAPK) inhibitor therapy, their tumor cells can upregulate stem cell marker expression including ALDH1 enzymes (Figure S1A).42 This evidence concerns the gene WNK2 and melanoma.